Treatment of excessive neovascularization
The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.
1 . A method of treating or preventing an angiogenesis-related disease in a subject, the method comprising administering stem cells, or progeny cells thereof, to the subject.
2 . The method of claim 1 , wherein the angiogenesis-related disease is selected from the group consisting of angiogenesis-dependent cancers, benign tumors, rheumatoid arthritis, psoriasis, ocular angiogenesis diseases, Osier-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, hypertrophic scars, cat scratch disease and Helicobacter pylori ulcers.
3 . The method of claim 2 , wherein the angiogenesis-related disease is an ocular angiogenesis disease.
4 . The method of claim 3 , wherein wherein the ocular angiogenesis disease is selected from the group consisting of: diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia and rubeosis.
5 . The method of claim 4 , wherein the ocular angiogenesis disease is macular degeneration or diabetic retinopathy.
6 . The method of claim 5 , wherein the macular degeneration is dry age-related macular degeneration or wet age-related macular degeneration.
7 . The method of claim 1 , wherein the stem cells are obtained from bone marrow.
8 . The method of claim 1 , wherein the stem cells are mesenchymal precursor cells (MPC).
9 . The method of claim 8 , wherein the mesenchymal precursor cells are TNAP + , STRO-1 + , VCAM-1 + , THY-1 + , STRO-2 + , CD45 + , CD146 + , 3G5 + or any combination thereof.
10 . The method of claim 9 , wherein at least some of the STRO-1 + cells are STRO-1 bri .
11 . The method of claim 1 , wherein the progeny cells are obtained by culturing mesenchymal precursor cells in vitro.
12 . The method of claim 1 , wherein at least some of the cells are genetically modified.
13 . The method of claim 1 , wherein the angiogenesis-related disease is an angiogenesis-dependent cancer or a benign tumour, and the cells are used to deliver an anti-cancer agent.
14 . (canceled)
15 . The method of claim 6 , wherein the stem cells are obtained from bone marrow.
16 . The method of claim 6 , wherein the stem cells are mesenchymal precursor cells (MPC).
17 . The method of claim 7 , wherein the stem cells are mesenchymal precursor cells (MPC).
18 . The method of claim 6 , wherein the progeny cells are obtained by culturing mesenchymal precursor cells in vitro.
19 . The method of claim 8 , wherein the progeny cells are obtained by culturing mesenchymal precursor cells in vitro.
20 . The method of claim 6 , wherein at least some of the cells are genetically modified.
21 . The method of claim 8 , wherein at least some of the cells are genetically modified.